William Blair Starts CATX Coverage With Outperform on Radiopharma Growth
William Blair initiated coverage on Perspective Therapeutics (CATX) with an Outperform rating, citing lead-212 radiopharmaceuticals and a robust peptide platform. The report notes a potential U.S. radiopharmaceutical market up to $35B and a de-risked pathway as manufacturing and regulatory dynamics improve. A fair-value of about $11.45 per share suggests meaningful upside if milestones are met.
View signal analysis